REFERENCES
- Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002; 54: 631–651
- Cavalli R., Gasco M. R., Barresi A. A., Rovero G. Evaporative drying of aqueous dispersions of solid lipid nanoparticles. Drug Dev. Ind. Pharm. 2001; 27: 919–924
- Cherian A. K., Rana A. C., Jain S. K. Self assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug Dev. Ind. Pharm. 2000; 26: 459–463
- Connors R. D., Elder E. J. Using a portfolio of particle growth technologies to enable delivery of drugs with poor water solubility. Drug Deliv. Tech. 2004; 4: 78–83
- Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev. 1998; 34: 221–233
- Dressman J. B., Reppas C. In vitro-in vivo correlation for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000; 11: S73–S80
- Elder E. J., Hitt J. E., Rogers T. L., Tucker C. J., Saghir S. A., Svenson S., Evans J. C. Particle engineering of poorly water soluble drugs by controlled precipitation. Polymeric Drug Delivery Volume II—Polymeric Matrices and Drug Particle Engineering (ACS Symposium Series), S. Svenson. American Chemical Society, Washington, DC 2006; 924: 292–304
- Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Q3C Impurities: Residual Solvents. Rockville, MD 1997
- Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Stability Testing of Drug Substances and Drug Products. Rockville, MD 1998
- Hoffart V., Ubrich N., Simonin C., Babak V., Vigneron C., Hoffman M., Lecompte T., Maincent P. Low molecular weight heparin-loaded polymeric nanoparticles: Formulation, characterization, and release characteristics. Drug Dev. Ind. Pharm. 2002; 28: 1091–1099
- Hu J., Johnston K. P., Williams R. O. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev. Ind. Pharm. 2004; 30: 233–245
- Merisko-Liversidge E., Liversidge G. G., Cooper E. R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003; 18: 113–120
- Muller R. H., Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int. J. Pharm. 1998; 160: 229–237
- Pace S. N., Pace G. W., Prikh I., Mishra A. K. Novel injectable formulations of insoluble drugs. Pharm. Technol. 1999; 3: 116–134
- Rambali B., Verreck G., Baert L., Massart D. L. Itraconazole formulation studies of the melt extrusion process with mixture design. Drug Dev. Ind. Pharm. 2003; 29: 641–652
- Rogers T. L., Gillespie I. B., Hitt J. E., Fransen K. L., Crowl C. A., Tucker C. J., Kupperblatt G. B., Becker J. N., Wilson D. L., Todd C., Broomall C. F., Evans J. C., Elder E. J. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm. Res. 2004; 21: 2048–2057
- Rogers T. L., Johnston K. P., Williams R. O. A comprehensive review: Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid CO2 and cryogenic spray-freezing technologies. Drug Dev. Ind. Pharm. 2001; 27: 1003–1015
- Rojanapanthu P., Sarisuta N., Chaturon K., Kraisintu K. Physicochemical properties of amphotericin B liposomes prepared by reverse phase evaporation method. Drug Dev. Ind. Pharm. 2003; 29: 31–37
- Santhi K., Dhanaraj S. A., Rajendran S. D., Raja K., Ponnusankar S., Suresh B. Nonliposomal approach—A study of preparation of egg albumin nanospheres containing amphotericin-B. Drug Dev. Ind. Pharm. 1999; 25: 547–551
- Serajuddin A. T. M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999; 88: 1058–1066
- Subramaniam B., Rajewski R. A., Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J. Pharm. Sci. 1997; 86: 885–890
- Tom J. W., Debenedetti P. G. Particle formation with supercritical fluids—A review. J. Aerosol Sci. 1991; 22: 555–584
- United States Pharmacopeia (USP) XXVII. General Chapter <905> Uniformity of Dosage Units—Weight Variation. Rockville, MD 2004; 2396–2397
- York P. Strategies for particle design using supercritical fluid technologies. PSST 1999; 2: 430–440